Clinical Trial Detail

NCT ID NCT03920839
Title INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors Incyte Corporation
Indications

malignant pleural mesothelioma

lung non-small cell carcinoma

Advanced Solid Tumor

Therapies

Carboplatin + Paclitaxel + Retifanlimab

Cisplatin + Gemcitabine + Retifanlimab

Cisplatin + Pemetrexed Disodium + Retifanlimab

Carboplatin + Pemetrexed Disodium + Retifanlimab

Age Groups: adult senior

No variant requirements are available.